Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
PROKIDNEY CORP (PROK)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.06-4.91%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PROK yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Funding runway extends into mid-2027 | The company aims to maintain funding into mid-2027. | Intact | funding runway falls short of mid-2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Second Quarter 2026 Financial Highlights Liquidity: Cash, cash equivalents and marketable securities as of June 30, 2026, totaled $181.6 million, compared to $224.9 million as of March 31, 2026.” “We expect that our existing cash, cash equivalents and marketable securities held at March 31, 2026, will enable us to fund our operating expenses and capital expenditure requirements into mid-2027.” Revenue was $0.150 million in 2026-Q2. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth business, not an established earnings compounder, because it is loss-making and recent financial performance is weak. The long-term thesis is on watch: management is progressing its key trial, but the risk level is high and the latest results remain below the industry cohort.
The evidence snapshot provides no valuation or expectations data, so whether PROK looks cheap or expensive versus peers cannot be assessed. The main known expectations are tied to clinical milestones and maintaining funding into mid-2027, rather than current earnings strength.
Near-term results face execution risk: PROK has a run of earnings misses, and the risk of another miss is elevated. Management remains on track to complete full PROACT 1 enrollment in 2026, with pivotal results anticipated in Q2 2027, while cash has fallen and operating losses have grown.
The multi-year thesis hinges on completing PROACT 1 enrollment and delivering the pivotal results on the stated timeline. Near-term risks include weaker guidance, continued cash burn, and a softer jobs backdrop; stronger results and guidance from healthcare peers could support sector momentum.
Over the next 1 to 3 years, PROK’s clinical progress is the main source of potential business change, while losses, cash use, and high execution risk remain central concerns. The evidence supports a watch-state long-term thesis, with medium confidence. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Operating losses remain controlled near -$45M quarterly | Revenue is stable near $226K quarterly. | Intact | operating losses worsen beyond -$50M next quarter | Operating income: $-48.373M FY2026-Q2; GAAP. Published target: >= -44.9 million USD operating loss next quarter. The target does not explicitly identify fiscal versus calendar quarters. Aug 10, 2026-48,373,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “G&A Expenses: General and administrative expenses were $12.4 million for the three months ended June 30, 2026, compared to $14.0 million for the same period in 2025.” “Additionally, professional fees and other operating costs decreased $0.4 million driven by ongoing initiatives, including the domestication and restructuring transactions in 2025.” Revenue was $0.150 million in 2026-Q2. Delivery assessment Nov 5, 2026 |
Quarterly revenue remains stable near $226K | Revenue is stable near $226K quarterly. | Broken | quarterly revenue falls below $200K next quarter | Revenue: $150,000 FY2026-Q2; GAAP. Published target: >= 220,000 USD quarterly revenue next quarter. The target does not explicitly identify fiscal versus calendar quarters. Aug 10, 2026150,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.66 → $-0.69 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.66 | $449,833 | 4 / 4 |
| 2026-07-25 | $-0.66 | $449,833 | 4 / 4 |
| 2026-07-26 | $-0.66 | $449,833 | 4 / 4 |
| 2026-07-27 | $-0.66 | $449,833 | 4 / 4 |
| 2026-07-28 | $-0.58 | $449,830 | 5 / 6 |
| 2026-07-29 | $-0.58 | $449,830 | 5 / 6 |
| 2026-07-30 | $-0.58 | $449,830 | 5 / 6 |
| 2026-07-31 | $-0.66 | $449,833 | 4 / 4 |
| 2026-08-01 | $-0.66 | $449,833 | 4 / 4 |
| 2026-08-02 | $-0.58 | $449,830 | 5 / 6 |
| 2026-08-03 | $-0.66 | $449,833 | 4 / 4 |
| 2026-08-04 | $-0.66 | $449,833 | 4 / 4 |
| 2026-08-05 | $-0.58 | $449,830 | 5 / 6 |
| 2026-08-06 | $-0.66 | $449,833 | 4 / 4 |
| 2026-08-07 | $-0.66 | $449,833 | 4 / 4 |
| 2026-08-08 | $-0.58 | $449,830 | 5 / 6 |
| 2026-08-09 | $-0.58 | $449,830 | 5 / 6 |
| 2026-08-10 | $-0.58 | $449,830 | 5 / 6 |
| 2026-08-12 | $-0.66 | $449,833 | 4 / 4 |
| 2026-08-13 | $-0.66 | $449,833 | 4 / 4 |
| 2026-08-14 | $-0.66 | $449,833 | 4 / 4 |
| 2026-08-15 | $-0.66 | $449,833 | 4 / 4 |
| 2026-08-16 | $-0.66 | $449,833 | 4 / 4 |
| 2026-08-17 | $-0.66 | $449,833 | 4 / 4 |
| 2026-08-18 | $-0.66 | $449,833 | 4 / 4 |
| 2026-08-19 | $-0.66 | $449,833 | 4 / 4 |
| 2026-08-20 | $-0.66 | $411,833 | 4 / 3 |
| 2026-08-21 | $-0.66 | $411,833 | 4 / 3 |
| 2026-08-22 | $-0.66 | $411,833 | 4 / 3 |
| 2026-08-23 | $-0.66 | $411,833 | 4 / 3 |
| 2026-08-24 | $-0.66 | $411,833 | 4 / 3 |
| 2026-08-25 | $-0.66 | $411,833 | 4 / 3 |
| 2026-08-26 | $-0.66 | $411,833 | 4 / 3 |
| 2026-08-27 | $-0.66 | $411,833 | 4 / 3 |
| 2026-08-28 | $-0.66 | $411,833 | 4 / 3 |
| 2026-08-29 | $-0.66 | $411,833 | 4 / 3 |
| 2026-08-30 | $-0.66 | $411,833 | 4 / 3 |
| 2026-08-31 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-01 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-02 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-03 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-04 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-05 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-06 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-07 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-08 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-09 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-10 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-11 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-12 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-13 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-14 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-15 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-16 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-17 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-18 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-19 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-20 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-21 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-22 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-23 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-24 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-25 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-26 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-27 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-28 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-29 | $-0.66 | $411,833 | 4 / 3 |
| 2026-09-30 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-01 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-02 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-03 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-04 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-05 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-06 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-07 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-08 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-09 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-10 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-11 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-12 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-13 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-14 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-15 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-16 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-17 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-18 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-19 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-20 | $-0.66 | $411,833 | 4 / 3 |
| 2026-10-21 | $-0.66 | $411,833 | 3 / 3 |
| 2026-10-22 | $-0.66 | $411,833 | 3 / 3 |
| 2026-10-23 | $-0.66 | $411,833 | 3 / 3 |
| 2026-10-24 | $-0.66 | $411,833 | 3 / 3 |
| 2026-10-25 | $-0.66 | $411,833 | 3 / 3 |
| 2026-10-26 | $-0.69 | $494,200 | 3 / 3 |
| 2026-10-27 | $-0.69 | $494,200 | 3 / 3 |
| 2026-10-28 | $-0.69 | $494,200 | 3 / 3 |
| 2026-10-29 | $-0.69 | $494,200 | 3 / 3 |
| 2026-10-30 | $-0.69 | $494,200 | 3 / 3 |
| 2026-10-31 | $-0.69 | $494,200 | 3 / 3 |
| 2026-11-01 | $-0.69 | $494,200 | 3 / 3 |
| 2026-11-02 | $-0.69 | $494,200 | 3 / 3 |
| 2026-11-03 | $-0.69 | $494,200 | 3 / 3 |
| 2026-11-04 | $-0.69 | $494,200 | 3 / 3 |
| 2026-11-05 | $-0.69 | $494,200 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 1 Hold · 1 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.